Short selling IMNP (Immune Pharmaceuticals) after it ran 125% on no news.
IMNP (Immune Pharmaceuticals) has a bearish long term chart and a very unhealthy balance sheet. Their recent 10-Q shows 22K in cash reserves and millions in short-term debt. They also lose millions in operating losses. After it ran 125% on no news, it was an obvious short play. The full version of this video will be featured in Paradigm Trade’s strategy video coming soon.